These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19763689)

  • 1. Oropharyngeal dysphagia in infants and children with infantile Pompe disease.
    Jones HN; Muller CW; Lin M; Banugaria SG; Case LE; Li JS; O'Grady G; Heller JH; Kishnani PS
    Dysphagia; 2010 Dec; 25(4):277-83. PubMed ID: 19763689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy.
    Fecarotta S; Ascione S; Montefusco G; Della Casa R; Villari P; Romano A; Del Giudice E; Andria G; Parenti G
    Ital J Pediatr; 2013 May; 39():30. PubMed ID: 23668440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M; Zhang L; Quan S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
    Del Rizzo M; Fanin M; Cerutti A; Cazzorla C; Milanesi O; Nascimbeni AC; Angelini C; Giordano L; Bordugo A; Burlina AB
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S389-93. PubMed ID: 20830524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early cognitive development in children with infantile Pompe disease.
    Spiridigliozzi GA; Heller JH; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2012 Mar; 105(3):428-32. PubMed ID: 22217428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement.
    Hobson-Webb LD; Jones HN; Kishnani PS
    Neuromuscul Disord; 2013 Apr; 23(4):319-23. PubMed ID: 23332114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractures in children with Pompe disease: a potential long-term complication.
    Case LE; Hanna R; Frush DP; Krishnamurthy V; DeArmey S; Mackey J; Boney A; Morgan C; Corzo D; Bouchard S; Weber TJ; Chen YT; Kishnani PS
    Pediatr Radiol; 2007 May; 37(5):437-45. PubMed ID: 17342521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.
    El-Gharbawy AH; Mackey J; DeArmey S; Westby G; Grinnell SG; Malovrh P; Conway R; Kishnani PS
    Mol Genet Metab; 2011; 104(1-2):118-22. PubMed ID: 21802969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging phenotype of long-term survivors with infantile Pompe disease.
    Prater SN; Banugaria SG; DeArmey SM; Botha EG; Stege EM; Case LE; Jones HN; Phornphutkul C; Wang RY; Young SP; Kishnani PS
    Genet Med; 2012 Sep; 14(9):800-10. PubMed ID: 22538254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
    Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van Mӧlken MPMH; Hakkaart-van Roijen L
    Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.
    Barker PC; Pasquali SK; Darty S; Ing RJ; Li JS; Kim RJ; DeArmey S; Kishnani PS; Campbell MJ
    Mol Genet Metab; 2010 Dec; 101(4):332-7. PubMed ID: 20875764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
    Papadopoulos C; Orlikowski D; Prigent H; Lacour A; Tard C; Furby A; Praline J; Solé G; Hogrel JY; De Antonio M; Semplicini C; Deibener-Kaminsky J; Kaminsky P; Eymard B; Taouagh N; Perniconi B; Hamroun D; Laforêt P;
    Mol Genet Metab; 2017 Sep; 122(1-2):80-85. PubMed ID: 28648663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy.
    van Gelder CM; van Capelle CI; Ebbink BJ; Moor-van Nugteren I; van den Hout JM; Hakkesteegt MM; van Doorn PA; de Coo IF; Reuser AJ; de Gier HH; van der Ploeg AT
    J Inherit Metab Dis; 2012 May; 35(3):505-11. PubMed ID: 22008944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early higher dosage of alglucosidase alpha in classic Pompe disease.
    Spada M; Pagliardini V; Ricci F; Biamino E; Mongini T; Porta F
    J Pediatr Endocrinol Metab; 2018 Dec; 31(12):1343-1347. PubMed ID: 30433875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When should we start enzyme replacement therapy for infantile Pompe disease with severe cardiomyopathy?
    Bonilla-Palomas JL; Gámez-López AL; Tejero-Hernández MA; Tejero-Mateo I; López-López J
    Rev Esp Cardiol (Engl Ed); 2012 Jan; 65(1):100-2. PubMed ID: 21715078
    [No Abstract]   [Full Text] [Related]  

  • 19. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.